B2M (Human) CRISPR/Cas9 Lentivirus (Non-Integrating)

78340

B2M (Human) CRISPR/Cas9 Lentivirus (Integrating)

Beta-2 Microglobulin (B2M) is a required component of Major Histocompatibility Complex (MHC) class 1 molecules, which present peptide fragments from within the cell to cytotoxic T-cells as part of the adaptive immune system. The B2M CRISPR/Cas9 Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 5 sgRNA (single guide RNAs) targeting human B2M driven by a U6 promoter.The integrating lentivirus integrates randomly into the cellular genome to express both Cas9 and the sgRNA. Puromycin selection forces high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Efficiencies will depend on the cell type and the gene of interest.

1342.5 €

78198

CD5 (Human) CRISPR/Cas9 Lentivirus (Non-Integrating)

The CD5 CRISPR Lentiviruses are replication incompetent, HIV-based VSV-G  pseudotyped lentiviral particles that are ready to  infect almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 5 sgRNA (single guide RNA) targeting human CD5 driven by a U6 promoter.The integrating lentivirus integrates randomly into the  cellular genome to express both Cas9 and the sgRNA. Puromycin selection forces high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Efficiencies may vary, depending on the cell type and the gene of interest.

1642.5 €

78434

CIITA (Human) CRISPR/Cas9 Lentivirus (Non-integrating)

CIITA (class II major histocompatibility complex transactivator) acts as a coactivator for MHC (major histocompatibility complex) class II-specific gene expression and negatively regulates the IL-4 gene promoter during T cell differentiation. IFN-γ (interferon-gamma) induces CIITA gene expression via Janus kinase 1) and Stat1 (Signal transducer and activator of transcription 1) pathways. The GTP-binding and acidic, proline-serine threonine-rich regions appear to be required for CIITA activity. Defects of CIITA has been implicated as causes of bare lymphocyte syndrome (BLS), which is characterized by the absence of MHC class II transcription and severe immunodeficiencies.The CIITA CRISPR/Cas9 Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 5 sgRNA (single guide RNAs) targeting human CIITA driven by a U6 promoter.Unlike CIITA CRISPR/Cas9 Lentivirus (Integrating) (BPS Bioscience #78435), the CIITA CRISPR/Cas9 Lentivirus (Non-Integrating) is made with a mutated Integrase, resulting in only transient expression of the Cas9 and CIITA targeting sgRNA. This transient expression minimizes potential off-target effects caused by either prolonged expression or random integration of Cas9 and the sgRNA. A short round of puromycin selection right after transduction may increase knockout efficiency, however puromycin should not be used for more than 48 hours post-transduction due to the transient nature of expression using the non-integrating lentivirus.

1642.5 €

MBS7608579-005mg

Recombinant Human B2M

624.88 €

MBS7608579-02mg

Recombinant Human B2M

994.62 €

MBS7608579-1mg

Recombinant Human B2M

2480 €